Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients.
Consuming one cup of caffeinated coffee statistically increases IOP and ocular perfusion pressure (OPP) in primary open-angle glaucoma (POAG) patients. patients, claims a paper in Eye.
Dr A.Z. Jiwani et al., Harvard Medical School, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA, conducted a prospective, double-masked, crossover, randomized controlled trial on 106 subjects. Of these participants, 22 had high-tension POAG, 18 had normal tension, 21 POAG suspects and 25 healthy volunteers.
Each subject was given either 237 mL of caffeinated coffee or decaffeinated coffee at the first visit and the alternate beverage on the second visit. The outcome measures included blood pressure (BP) and pascal dynamic contour tonometer measurements of IOP ocular pulse amplitude (OPA) and heart rate. These were all measured before and at 60 and 90 minutes after coffee ingestion.
The results demonstrated no significant difference in baseline IOP, OPP and OPA between caffeinated and decaffeinated drinks. Mean mmHg changes in IOP, OPP and OPA were 0.99, 1.57 and 0.23, at 60 minutes, respectively. The results at 90 minutes for IOP, OPP and OPA were and 1.06, 1.26 and 0.18, respectively.
This suggests that consuming one cup of caffeinated coffee statistically increases but is not likely to clinically impact IOP and OPP in POAG cases.
The abstract can be found here .
AAO 2024: Transient vision loss with Alexander Fein, MD
October 21st 2024Alexander Fein, MD, spoke with the Eye Care Network to share how to approach a patient presenting with transient vision loss, what this type of vision loss can mean, and what additional testing might be needed to determine the best plan for care.
AAO 2024: Optimal pupil size reduction percentage for near vision improvement in presbyopia
October 21st 2024Jennifer Loh, MD, shared insights from on her presentation at the American Academy of Ophthalmology meeting in Chicago on the effects of CSF-1, which is the lowest effective concentration of pilocarpine approved in the United States.